Follow The Filings

CAPR

Health Care, filed as CAPRICOR THERAPEUTICS INC (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.8%
  • $5.5M
  • 1 exit

In 2026 Q2 Farallon Capital Management sold out of CAPR.

Who owns this now

Largest portfolio weights among holders, up to 0.8% (Palo Alto Investors). Not free-float ownership.

  1. Palo Alto Investors 0.76%

Who owns CAPR

Sorted by value, long equity only, as of 2026 Q2.

History
Palo Alto Investors 0.76% Hold 229,763 $5.5M History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 0.01% Exit −0.01% 41,000 $1.2M History

1 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by CAPR's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CAPR insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $8.4M sold by 3 insiders under 10b5-1 plans
  1. Anthony Bergmann CFO
    Planned sale
    $732K 24,100 shares at $30.38 68% of stake
    Traded Jun 25 Filed Jun 29
    ↗
  2. Anthony Bergmann CFO
    Planned sale
    $27K 900 shares at $30.00 7.4% of stake
    Traded Jun 22–24 Filed Jun 24
    ↗
  3. Anthony Bergmann CFO
    Planned sale
    $793K 25,000 shares at $31.70 75% of stake
    Traded May 1 Filed May 4
    ↗
  4. Karen Krasney EVP, General Counsel
    Planned sale
    $793K 25,000 shares at $31.70 45% of stake
    Traded May 1 Filed May 4
    ↗
  5. Karimah Es Sabar Director
    Planned sale
    $241K 7,529 shares at $32.00 100% of stake
    Traded Apr 2 Filed Apr 3
    ↗
  6. Karimah Es Sabar Director
    Planned sale
    $3.5M 115,000 shares at $30.57 100% of stake
    Traded Mar 31–Apr 1 Filed Apr 1
    ↗
  7. Anthony Bergmann CFO
    Planned sale
    $753K 25,000 shares at $30.13 75% of stake
    Traded Mar 31 Filed Apr 1
    ↗
  8. Karen Krasney EVP, General Counsel
    Planned sale
    $753K 25,000 shares at $30.12 45% of stake
    Traded Mar 31 Filed Apr 1
    ↗

Also filed in the last 12 months, not counted as buying or selling: 19 option exercises.

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 1.01,2.03 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
DEF 14A Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 12 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $25.18M $22.27M $0M
Net income -$22.29M -$40.47M -$105.04M
Net margin * -88.5% -181.7% —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $50.86M $163.39M $322.94M
Total non-current assets * $7.88M $7.1M $33.01M
Total assets $58.73M $170.48M $355.95M
Total current liabilities $31.27M $21.03M $35.84M
Total non-current liabilities $4.86M $3.99M $14.32M
Total equity $22.6M $145.46M $305.79M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$25.6M -$40M -$69.81M
Cash from investing $5.11M -$116.18M $97.48M
Cash from financing $25.58M $152.77M $248.89M
Net change in cash * $5.09M -$3.41M $276.56M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.